Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group

Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer

“…The objective response rate was 43% and, therefore, in the range of those seen in other recent induction chemotherapy trials that enrolled both cIIIA and cIIIB patients [10,11]. No differences in the response pattern between stage IIIA and IIIB subsets were observed, which is consistent on data from induction chemoradiotherapy [12].…”

Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer

“…10 -12 When combined with cisplatin and/or paclitaxel or vinorelbine, gemcitabine therapy shows an objective response rates in 28 -54% and the median survival durations ranged from 38 to 61.5 weeks. [13][14][15][16][17][18] However, the treatment of advanced lung cancer still remains a challenge to medical oncologists.Because of differences in mechanisms of action and toxicity profiles, the combination of the above 2 agents may have clinical potential. The present study was designed to determine whether gemcitabine potentiates the antitumor activity of VSV in vitro using both A549 (human lung adenocarcinoma) and LLC (murine Lewis lung carcinoma) cell lines and in vivo using A549 lung cancer xenografts and the murine syngeneic Lewis lung cancer, and if so, to examine the possible mechanism in the phenomenon, as well as to provide some potential implications for the treatment of human lung cancer.…”

“…10 -12 When combined with cisplatin and/or paclitaxel or vinorelbine, gemcitabine therapy shows an objective response rates in 28 -54% and the median survival durations ranged from 38 to 61.5 weeks. [13][14][15][16][17][18] However, the treatment of advanced lung cancer still remains a challenge to medical oncologists.…”

Quercetin Enhances Chemosensitivity to Gemcitabine in Lung Cancer Cells by Inhibiting Heat Shock Protein 70 Expression

“…The response rate to gemcitabine in the advanced stages of NSCLC is approximately 25%, and the response rate increases to 54% when it is combined with platinum. 33,34 Although the mechanism related to gemcitabine resistance in NSCLC is not fully understood, evidence suggests that insufficient intracellular concentrations of the active moiety and alterations in the associated apoptotic mechanism might contribute to this resistance. 35 Similar to previous studies that investigated the effect of quercetin on gemcitabinetreated fibrosarcoma cells and pancreatic cancer cells, 36,37 the present data show that quercetin-induced HSP70 inhibition enhanced the anticancer activity of gemcitabine in lung cancer cells.…”